# A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)

> **NCT00401596** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 1899 (—)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Xolair (omalizumab)

## Key facts

- **NCT ID:** NCT00401596
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-07
- **Primary completion:** —
- **Final completion:** 2002-07
- **Target enrollment:** 1899 (—)
- **Last updated:** 2014-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00401596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00401596, "A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00401596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*